Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Wendy Sanderson"'
Autor:
Suzanne Ackloo, Albert A. Antolin, Jose Manuel Bartolome, Hartmut Beck, Alex Bullock, Ulrich A. K. Betz, Jark Böttcher, Peter J. Brown, Menorca Chaturvedi, Alisa Crisp, Danette Daniels, Jan Dreher, Kristina Edfeldt, Aled M. Edwards, Ursula Egner, Jon Elkins, Christian Fischer, Tine Glendorf, Steven Goldberg, Ingo V. Hartung, Alexander Hillisch, Evert Homan, Stefan Knapp, Markus Köster, Oliver Krämer, Josep Llaveria, Uta Lessel, Sven Lindemann, Lars Linderoth, Hisanori Matsui, Maurice Michel, Florian Montel, Anke Mueller-Fahrnow, Susanne Müller, Dafydd R. Owen, Kumar Singh Saikatendu, Vijayaratnam Santhakumar, Wendy Sanderson, Cora Scholten, Matthieu Schapira, Sujata Sharma, Brock Shireman, Michael Sundström, Matthew H. Todd, Claudia Tredup, Jennifer Venable, Timothy M. Willson, Cheryl H. Arrowsmith
Publikováno v:
RSC Medicinal Chemistry.
Target 2035, an international federation of biomedical scientists from the public and private sectors, is leveraging ‘open’ principles to develop a pharmacological tool for every human protein.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3307d439e596fca276308b7255fe64f6
https://doi.org/10.1039/d2md00441k
https://doi.org/10.1039/d2md00441k
Autor:
José Manuel Bartolomé-Nebreda, Marijke Somers, Laura Iturrino, Greet Vanhoof, Joaquín Pastor, Susana Conde-Ceide, María Luz Martín-Martín, Xavier Langlois, Gregor James Macdonald, Anton Megens, Francisca Delgado, Wendy Sanderson, Carlos M. Martínez-Viturro, Han Min Tong
Publikováno v:
Journal of Medicinal Chemistry. 57:4196-4212
We report the discovery of a series of imidazo[1,2-a]pyrazine derivatives as novel inhibitors of phosphodiesterase 10A (PDE10A). In a high-throughput screening campaign we identified the imidazopyrazine derivative 1, a PDE10A inhibitor with limited s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ac9ae359ff0523ce350342854294aa
https://doi.org/10.1021/jm500073h
https://doi.org/10.1021/jm500073h
Autor:
Luca A. Fenu, Eva Hoeben, Achiel Van Peer, Ron Gilissen, Karin Vaarties, Stefan De Buck, Wendy Sanderson, Marjoleen J.M.A Nijsen, Johan W. Smit, Kelly Van Uytsel, Vikash K. Sinha, Claire Mackie
Publikováno v:
Clinical Pharmacokinetics. 50:307-318
Background: It is imperative that new drugs demonstrate adequate pharmacokinetic properties, allowing an optimal safety margin and convenient dosing regimens in clinical practice, which then lead to better patient compliance. Such pharmacokinetic pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::759287a16bc429d7831cef21564684ba
https://doi.org/10.2165/11539250-000000000-00000
https://doi.org/10.2165/11539250-000000000-00000
Autor:
Andrés A. Trabanco, Meri De Angelis, Peter Jacobus Johannes Antonius Buijnsters, Wendy Sanderson, Alison Ritchie, Greet Vanhoof, Xavier Langlois, Yves Emiel Maria Van Roosbroeck, Gary Tresadern, Frederik J. R. Rombouts, José-Ignacio Andrés
Publikováno v:
ACS medicinal chemistry letters. 5(9)
Structure-guided design led to the identification of the novel, potent, and selective phosphodiesterase 2 (PDE2) inhibitor 12. Compound 12 demonstrated a >210-fold selectivity versus PDE10 and PDE11 and was inactive against all other PDE family membe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0c2fc29e7e676e20fb45578d45ffa03
https://pubmed.ncbi.nlm.nih.gov/25221665
https://pubmed.ncbi.nlm.nih.gov/25221665